Saturday, June 25, 2016 6:30:50 PM
DNAI ... DNA interference (DNAi) technology platform for patients with cancer and hematological diseases.
http://247wallst.com/healthcare-business/2016/06/12/7-biopharma-companies-that-destroyed-shareholders-last-week/
Perhaps the biggest loser from ASCO thus far is ProNAi Therapeutics Inc. (NASDAQ: DNAI). The company announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Results from this mid-stage trial were disappointing and modest efficacy was seen, at best.
Unfortunately, ProNAi has decided to go in a different direction and is suspending its development of PNT2258 and will focus its resources elsewhere.
Over the course of the past week, the stock dropped 68.8%. Shares of ProNAi closed Friday at $1.99, with a consensus analyst price target of $11.63 and a 52-week trading range of $1.98 to $33.75.???
DNAI DNA interference (DNAi) technology platform for patients with cancer and hematological diseases.
http://247wallst.com/healthcare-business/2016/06/12/7-biopharma-companies-that-destroyed-shareholders-last-week/
Perhaps the biggest loser from ASCO thus far is ProNAi Therapeutics Inc. (NASDAQ: DNAI). The company announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Results from this mid-stage trial were disappointing and modest efficacy was seen, at best.
Unfortunately, ProNAi has decided to go in a different direction and is suspending its development of PNT2258 and will focus its resources elsewhere.
Over the course of the past week, the stock dropped 68.8%. Shares of ProNAi closed Friday at $1.99, with a consensus analyst price target of $11.63 and a 52-week trading range of $1.98 to $33.75.???
DNAI DNA interference (DNAi) technology platform for patients with cancer and hematological diseases.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
